Management of Fungal Infections in Immunocompromised Patients

Diagnostic Considerations

The Infectious Diseases Society of America recommends that immunocompromised patients with suspected fungal infection require immediate empirical antifungal therapy while diagnostic workup proceeds, as delayed treatment significantly increases mortality 1, 2
High-risk patient populations, such as those with hematologic malignancies with prolonged neutropenia, represent the highest risk group for fungal infections 3
Patients receiving high-dose corticosteroids or T-cell immunosuppressants are also at elevated risk for fungal infections 3
AIDS patients with CD4 counts <200 cells/mm³ are at elevated risk for Pneumocystis jirovecii and cryptococcal infections 4
Solid organ transplant recipients, especially lung transplant patients with anastomotic site infections, are at increased risk for fungal infections 4

The American College of Clinical Pharmacy recommends starting an echinocandin immediately for suspected invasive candidiasis with elevated liver enzymes, as first-line therapy due to minimal hepatotoxicity 2
Lipid formulation amphotericin B is an alternative if echinocandins cannot be used, though nephrotoxicity risk exists 2
Voriconazole is the preferred first-line agent for invasive aspergillosis in most guidelines 8, 4
Liposomal amphotericin B or amphotericin B lipid complex are first-line options for suspected mucormycosis 1

The Infectious Diseases Society of America recommends continuing antifungal therapy for a minimum of 2 weeks after documented bloodstream clearance and symptom resolution for candidemia 2
Treatment duration for other fungal infections, such as cryptococcal meningitis, may be longer, typically 10-12 weeks after CSF becomes culture-negative for initial therapy 7
Monitoring parameters, including repeat blood cultures, serial imaging, and renal function monitoring, are essential to assess response to therapy and potential adverse effects 2, 6, 4

The Centers for Disease Control and Prevention recommend fluconazole prophylaxis for patients undergoing bone marrow transplantation, starting several days before anticipated neutropenia and continuing 7 days after neutrophil count >1000 cells/mm³ 7
Pneumocystis prophylaxis is recommended for all patients receiving bispecific antibody therapy due to high incidence and mortality 7

The American Association for the Study of Liver Diseases recommends using echinocandins in patients with hepatic dysfunction due to minimal hepatotoxicity compared to azoles 2
The European Society for Medical Oncology recommends that persistence of neutropenia is the most important factor associated with poor outcome in fusariosis and other invasive fungal infections; immune reconstitution is critical 6
The International Society for Heart and Lung Transplantation recommends heightened surveillance for allogeneic HSCT recipients with GVHD requiring corticosteroids, as they represent an extremely high-risk population 3